Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Nathalie I BouwerT G SteenbruggenJ van RosmalenH N RierJ J E M KitzenM L van BekkumA J Ten TijeP C de JongJ C DroogerC HolterhuesC H SmorenburgM J M KofflardE BoersmaG S SonkeM-D LevinA JagerPublished in: Breast cancer research and treatment (2021)
Serial cardiac monitoring can be safely omitted in non-smoking patients with baseline LVEF > 60% and without cardiotoxicity during prior neoadjuvant/adjuvant treatment.